Prediction: 1 Value Stock That Will Be Worth More Than Palantir by the End of 2026

Palantir has enjoyed massive post-IPO gains (up ~1,700%) but remains highly valued relative to fundamentals—about $400 billion market cap against under $4 billion in revenue and roughly $850 million EBIT (P/E ~391)—raising the risk of investor disappointment; by contrast, Philip Morris International offers a much cheaper valuation (P/E ~28, market cap ~$243 billion) and strong cash generation (roughly $10 billion LTM free cash flow, $13.5 billion EBIT) supported by resilient smokeables (volumes down only 1.3% YTD, revenue +1% YTD) and rapidly growing smoke-free brands (Zyn: ~205 million cans last quarter, +37% YoY; smoke-free revenue +16.1% YTD, 41% of revenues). The piece argues that given PM’s combination of steady cash flow and faster-growing smokefree initiatives versus Palantir’s richly priced growth, Philip Morris is a superior value and could surpass Palantir’s market capitalization by the end of 2026 if current trends continue.

Analysis

Palantir has delivered outsized equity returns since its IPO (up ~1,700%) but the article highlights a sharp valuation mismatch: a ~20% recent drawdown notwithstanding, the stock trades at a roughly $400 billion market capitalization against under $4 billion in revenue and approximately $850 million in EBIT, implying a P/E near 391 and pricing in many years of growth. The piece argues this gap makes Palantir vulnerable to investor disappointment if high growth does not materialize to justify the premium.

Philip Morris International presents the contrasting fundamental case: a ~$243 billion market cap, P/E ~28, and substantial cash generation (about $10 billion LTM free cash flow and $13.5 billion EBIT). Core smokeables remain resilient (smokeable volumes down only 1.3% year-to-date through nine months of 2025 and smokeables revenue +1% YTD) while smoke-free brands are accelerating (Zyn ~205 million U.S. cans last quarter, +37% YoY; smoke-free net revenue +16.1% YTD and 41% of net revenues).

Given the large valuation gulf, the article concludes Philip Morris could surpass Palantir in market capitalization by end-2026 if current trends persist. Investors should weigh PM's cash-flow and lower multiple against PLTR's growth premium and monitor execution on smoke-free growth and Palantir's revenue/earnings trajectory as key catalysts or risks.

Key Decisions for Investors

• Consider overweighting Philip Morris versus Palantir on a valuation and cash-flow basis given PM's ~P/E 28, ~$10bn LTM free cash flow and accelerating smoke-free revenue growth
• Avoid initiating or materially adding to Palantir positions at current multiples (market cap ~$400bn versus <$4bn revenue and ~ $850m EBIT) unless company-level growth and profitability metrics accelerate to justify the premium
• Monitor Philip Morris smoke-free KPIs (Zyn cans sold, smoke-free net revenue share) and smokeables volume/revenue trends through quarterly reports as primary catalysts for upside versus Palantir
• Maintain position sizing discipline and consider hedges or stop-losses for exposure to Palantir given downside risk if growth disappoints, and reassess allocations if Palantir reports sustained margin and revenue expansion